## PATENT APPLICATION

Date: October 31, 2006

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jérôme BESSE Atty. Docket No. 103120-00072

Serial No.: 10/567,345 Examiner:

Filed: February 6, 2006 Art Unit:

For: SOLID DISPERSIBLE AND/OR ORODISPERSIBLE NON-FILMY

CONTAINING AT LEAST ONE TYPE OF ACTIVE SUBSTANCE PHARMACEUTICAL COMPOSITION AND METHOD FOR THE

PREPARATION THEREOF

## **INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached Form PTO-SB08a. Unless otherwise indicated herein, one copy of each item(s) is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

	·
merits	This Information Disclosure Statement is being filed (a) within three months U.S. filing date, OR (b) before the mailing date of a first Office Action on the in the present application, OR (c) accompanies a Request for Continued ination. No certification or fee is required.
	This Information Disclosure Statement is being filed more than three months the U.S. filing date AND after the mailing date of the first Office Action on the s, but before the mailing date of a Final Rejection or Notice of Allowance.
	a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
	b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making

reasonable inquiry, was known to any individual designated in 37 CFR

		§1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
		c. A check in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
	Allowa the Info amoun charge	This Information Disclosure Statement is being filed more than three months are U.S. filing date and after the mailing date of a Final Rejection or Notice of nce, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that formation Disclosure Statement be considered. Attached is our check in the set of \$180.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 aded to ensure consideration of the disclosed information.
		a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
		b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
$\boxtimes$		The reference(s) was/were cited in a counterpart foreign application. An language version of the foreign search report is attached for the Examiner's ation. Copy/Copies of the U.S. Patent reference(s) is/are not enclosed.
	author	event that any fees are due with respect to this paper, the Commissioner is ized to charge such fees to Deposit Account No. 01-2300, referencing Atty. 3120-00072.
		Respectfully submitted,  George E. Gram, Jr.  Registration No. 27,931
O 4		2/12/

Customer No. 004372 ARENT FOX PLLC 1050 Connecticut Avenue, N.W., Suite 400 Washington, D.C. 20036-5339

Tel: (202) 857-6000 Fax: (202) 638-4810

GEO/ars

Enclosures: International Search Report; Form PTO-SB08a; References (3)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

			act of 1995, no person	s are required to respond to a collection	are required to respond to a collection of information unless it contains a valid OMB control number.			
	Substitute for form 1449A/	PTO		į	Complete if Known			
	INFORMATION	I DISCI	OSLIDE	Application Number	10/567,345			
				Filing Date	February 6, 2006			
	STATEMENT E			First Named Inventor	Jérôme BESSE			
	Form PT	O/SB/08a	3	Art Unit				
		Examiner Name						
Sheet	1	of	1	Attorney Docket Number	103120-00072			

			U.S. P.	ATENT DOCU	JMENTS	
Examiner Initials*	Cite No.1	Document Number	Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 6,358,526	B1	03-19-2002	William J. MERGENS et al	
_		US- 6,100,300	Α	08-08-2000	Karen M. ROGOSKY	
		US- 6,117,451	Α	09-12-2000	Vijai KUMAR	
		US-				
		US-				
		US-				
	1	US-				
		US-				
	<u> </u>	US-				
		US-				
		US-				
		US-				
	1	US-				
		US-				
		US-				
-		US-				
		US-	····			
		US-				
	1	US-				
		US-				
		US-				
		US-				

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document	Country Code <sup>3</sup>	Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁰	
		01/35941	wo	A2	05-25-2001	SmithKline Beecham Pharmaceuticals			
		02/047607	wo	A3	06-20-2002	Ranbaxy Laboratories Limited			
	<u> </u>	03/051293	wo	A2	06-26-2003	Bristol-Myers Squibb Company			
<u></u>									
-				1					
	<u> </u>								
								L	

Examiner Date Signature Considered			
Signature	Examiner	Date	
Olgitature Control Con	Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.